Ads
related to: anti parkinsonism- Our Mission
We're here for a Parkinson's cure
We put patients first
- Parkinson's Research News
The latest developments in research
Our research progress to date
- Get Involved Today
Join our mission to end Parkinson's
You can make a difference
- Understanding Parkinson's
Learn the basics of Parkinson's
Tips and Resources
- Our Mission
Search results
Results from the WOW.Com Content Network
These agents are used to treat Parkinson's disease. Anti-Parkinsonian Drugs include: Anticholinergic Agents; COMT Inhibitors; Dopamine Agonists; Levodopa; MAO-B Inhibitors
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
Parkinson's typically manifests in individuals over 60, with about one percent affected. In those younger than 50, it is termed "early-onset PD". No cure for Parkinson's is known, and treatment focuses on alleviating symptoms. Initial treatment typically includes L-DOPA, MAO-B inhibitors, or dopamine agonists.
Antimuscarinics are also used as anti-parkinsonian drugs. In parkinsonism, there is imbalance between levels of acetylcholine and dopamine in the brain, involving both increased levels of acetylcholine and degeneration of dopaminergic pathways (nigrostriatal pathway). Thus, in parkinsonism there is decreased level of dopaminergic activity.
Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia (slowed movements), rigidity, and postural instability. [ 1 ] [ 2 ] Both hypokinetic (bradykinesia and akinesia) as well as hyperkinetic (cogwheel rigidity and tremors at rest) features are displayed by Parkinsonism. [ 3 ]
The recommended dosing schedule of selegiline in Parkinson's disease (10 mg/day) has been described as somewhat questionable and potentially excessive from a pharmacological standpoint. [ 40 ] [ 36 ] Selegiline has been predicted to inhibit platelet MAO-B activity by approximately 95% or more after 96 hours with 2.5 mg/day, after 48 hours with ...
Trial results indicated that the viability of A 2A receptor antagonists have potential advantages over the current standard treatments for Parkinson's disease. [5] Several xanthines and non-xanthines are under development as potential anti-parkinsonism agents, which are selective for A 2A receptors.
These drugs are a different type of MAO inhibitor known as selective MAO inhibitors that are often prescribed for Parkinson's disease. [8] Many drug interactions involving selegiline are theoretical, primarily based on interactions with non-selective MAO inhibitors; at oral doses the risk of these interactions may be very low.
Ads
related to: anti parkinsonism